Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 54


Pharmacologic inhibition of JAK-STAT signaling promotes hair growth.

Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, Christiano AM.

Sci Adv. 2015 Oct 23;1(9):e1500973. eCollection 2015 Oct.


Current stage in inflammatory bowel disease: What is next?

Gómez-Gómez GJ, Masedo Á, Yela C, Martínez-Montiel Mdel P, Casís B.

World J Gastroenterol. 2015 Oct 28;21(40):11282-303. doi: 10.3748/wjg.v21.i40.11282. Review.


Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis.

Maiga M, Ahidjo BA, Maiga MC, Cheung L, Pelly S, Lun S, Bougoudogo F, Bishai WR.

EBioMedicine. 2015 Jul 14;2(8):866-71. doi: 10.1016/j.ebiom.2015.07.014. eCollection 2015 Aug.


The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases.

Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K.

Arch Immunol Ther Exp (Warsz). 2015 Dec;63(6):435-49. doi: 10.1007/s00005-015-0344-z. Epub 2015 Jun 11.


Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.

Valenzuela F, Papp KA, Pariser D, Tyring SK, Wolk R, Buonanno M, Wang J, Tan H, Valdez H.

BMC Dermatol. 2015 May 8;15:8. doi: 10.1186/s12895-015-0025-y.


Impact of irradiation and immunosuppressive agents on immune system homeostasis in rhesus macaques.

Meyer C, Walker J, Dewane J, Engelmann F, Laub W, Pillai S, Thomas CR Jr, Messaoudi I.

Clin Exp Immunol. 2015 Sep;181(3):491-510. doi: 10.1111/cei.12646. Epub 2015 Jun 29.


Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.

Namour F, Diderichsen PM, Cox E, Vayssière B, Van der Aa A, Tasset C, Van't Klooster G.

Clin Pharmacokinet. 2015 Aug;54(8):859-74. doi: 10.1007/s40262-015-0240-z.


Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.

Panés J, Su C, Bushmakin AG, Cappelleri JC, Mamolo C, Healey P.

BMC Gastroenterol. 2015 Feb 5;15:14. doi: 10.1186/s12876-015-0239-9.


Biological therapy for ulcerative colitis: an update.

Seo GS, Chae SC.

World J Gastroenterol. 2014 Oct 7;20(37):13234-8. doi: 10.3748/wjg.v20.i37.13234. Review.


Dry eye: an inflammatory ocular disease.

Hessen M, Akpek EK.

J Ophthalmic Vis Res. 2014 Apr;9(2):240-50. Review.


Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L, Singh P, Petukhova L, Mackay-Wiggan J, Christiano AM, Clynes R.

Nat Med. 2014 Sep;20(9):1043-9. doi: 10.1038/nm.3645. Epub 2014 Aug 17.


Update on Janus kinase antagonists in inflammatory bowel disease.

Boland BS, Sandborn WJ, Chang JT.

Gastroenterol Clin North Am. 2014 Sep;43(3):603-17. doi: 10.1016/j.gtc.2014.05.011. Epub 2014 Jun 24. Review.


Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.

Onda M, Ghoreschi K, Steward-Tharp S, Thomas C, O'Shea JJ, Pastan IH, FitzGerald DJ.

J Immunol. 2014 Jul 1;193(1):48-55. doi: 10.4049/jimmunol.1400063. Epub 2014 Jun 2.


JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.

Hsu L, Armstrong AW.

J Immunol Res. 2014;2014:283617. doi: 10.1155/2014/283617. Epub 2014 May 5. Review.


What is the future of targeted therapy in rheumatology: biologics or small molecules?

Mócsai A, Kovács L, Gergely P.

BMC Med. 2014 Mar 13;12:43. doi: 10.1186/1741-7015-12-43. Review.


In vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infection.

Takahashi Y, Byrareddy SN, Albrecht C, Brameier M, Walter L, Mayne AE, Dunbar P, Russo R, Little DM, Villinger T, Khowawisetsut L, Pattanapanyasat K, Villinger F, Ansari AA.

PLoS Pathog. 2014 Mar 6;10(3):e1003929. doi: 10.1371/journal.ppat.1003929. eCollection 2014 Mar.


Advances in treating psoriasis.

Belge K, Brück J, Ghoreschi K.

F1000Prime Rep. 2014 Jan 2;6:4. doi: 10.12703/P6-4. eCollection 2014. Review.


Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.

Meyer SC, Levine RL.

Clin Cancer Res. 2014 Apr 15;20(8):2051-9. doi: 10.1158/1078-0432.CCR-13-0279. Epub 2014 Feb 28. Review.


Inhibition of TAK1 and/or JAK can rescue impaired chondrogenic differentiation of human mesenchymal stem cells in osteoarthritis-like conditions.

van Beuningen HM, de Vries-van Melle ML, Vitters EL, Schreurs W, van den Berg WB, van Osch GJ, van der Kraan PM.

Tissue Eng Part A. 2014 Aug;20(15-16):2243-52. doi: 10.1089/ten.TEA.2013.0553. Epub 2014 Mar 25.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk